NEW YORK (GenomeWeb) – Foundation Medicine said today that it has received approval from the New York State Clinical Laboratory Evaluation Program for its FoundationACT blood-based circulating tumor DNA assay. All of its genomic profiling tests are now available in all 50 states, the company said.
FoundationACT has been analytically validated to detect genomic alterations in more than 60 of the most clinically relevant cancer genes in solid tumors, according to the firm. "We believe New York state conducts one of the most rigorous assessments of laboratory-developed tests in the nation, and its approval of FoundationACT speaks to the quality and reliability of our assay," said Jeffrey Ross, the company's medical director, in a statement.